Dr. Reddy's Laboratories Limited (BOM:500124)
India
· Delayed Price · Currency is INR | Market Cap | 1.06T |
| Revenue (ttm) | 342.15B |
| Net Income (ttm) | 58.62B |
| Shares Out | 832.52M |
| EPS (ttm) | 70.30 |
| PE Ratio | 18.14 |
| Forward PE | 21.04 |
| Dividend | 8.00 (0.63%) |
| Ex-Dividend Date | Jul 10, 2025 |
| Volume | 164,697 |
| Average Volume | 62,600 |
| Open | 1,277.00 |
| Previous Close | 1,277.00 |
| Day's Range | 1,271.95 - 1,282.70 |
| 52-Week Range | 1,025.90 - 1,404.60 |
| Beta | 0.35 |
| RSI | 61.25 |
| Earnings Date | Jan 22, 2026 |
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages i... [Read more]
Financial Performance
In 2024, Dr. Reddy's Laboratories's revenue was 325.54 billion, an increase of 16.61% compared to the previous year's 279.16 billion. Earnings were 56.54 billion, an increase of 1.54%.
Financial StatementsNews
JSW Steel, Kotak Mahindra & more: Top stocks to buy today — Check list
Brokerage firms are bullish on JSW Steel and Tata Consumer Products, forecasting significant growth. Aurobindo Pharma shows strong momentum. Kotak Mahindra Bank might acquire IDBI Bank, a move that co...
Dr Reddys, Titan & more: Top stocks to buy on December 3 — Check list
Leading financial institutions are bullish on select Indian stocks. HSBC recommends Dr Reddy's Labs for its semaglutide prospects, while Goldman Sachs sees strong growth for Titan's jewellery and othe...
Dr Reddy’s can make Novo’s weight loss drug, rules HC
India Business News: NEW DELHI: In a significant development in the blockbuster weight loss drug space, Delhi High Court has allowed Dr Reddy’s Labs to manufacture and exp.
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies
BANGALORE, India--(BUSINESS WIRE)-- #AurigeneOncology--Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112.
Nifty 50 top gainers today, December 2: Asian Paints, Dr. Reddy’s Laboratories, Maruti Suzuki India, Bharti Airtel and more
Indian equity benchmarks ended in the red on December 2, with both major indices slipping amid broad-based weakness. The Sensex...
Dr. Reddy’s Laboratories arm Aurigene Oncology receives GST appellate order
Dr. Reddy’s Laboratories informed the exchanges that its wholly owned subsidiary Aurigene Oncology Limited has received an order from the...
Biosimilar push: Dr Reddy’s gets EU nod for denosumab copy; Prolia, Xgeva rivals set for rollout
Dr. Reddy's Laboratories has achieved a significant regulatory win with the European Commission approving AVT03, its biosimilar for osteoporosis treatment. This authorization extends across all EU nat...
Dr. Reddy’s Laboratories receives European Commission approval for AVT03
Dr. Reddy’s Laboratories Ltd. announced that the European Commission (EC) has granted marketing authorization for AVT03, a biosimilar to Prolia®...
Dr. Reddy's Laboratories Breaks Above 200-Day Moving Average - Bullish for RDY
In trading on Wednesday, shares of Dr. Reddy's Laboratories Ltd. (Symbol: RDY) crossed above their 200 day moving average of $14.08, changing hands as high as $14.10 per share. Dr. Reddy's Laboratorie...
Dr. Reddy’s API facility clears USFDA GMP inspection with zero observations
Dr. Reddy’s Laboratories announced that the US Food & Drug Administration (USFDA) has completed a GMP inspection at its API...
How Hackers Duped Drugmakers Dr Reddy's, Group Pharmaceuticals Of Rs 2 Crore
In a major case of cyber fraud, a sum of Rs 2.16 crore has been siphoned off after fraudsters hacked email communications between Bengaluru-based Group Pharmaceuticals Ltd and Dr. Reddy's Laboratories...
Dr. Reddy's Laboratories Becomes Oversold (RDY)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Dr. Reddy’s Laboratories shares fall over 4% after delay in Semaglutide approval in Canada
Dr. Reddy’s Laboratories’ shares fell more than 4% in early trade on Thursday, October 30, after the company announced a...
Dr. Reddy's: Underappreciated Future Amid Exaggerated Headwinds
Dr. Reddy's Laboratories remains a compelling buy due to underappreciated growth in biosimilars and GLP-1 segments, despite near-term headwinds. RDY's Q2 FY26 results showed modest revenue growth, wit...
RDY Crosses Below Key Moving Average Level
In trading on Wednesday, shares of Dr. Reddy's Laboratories Ltd. (Symbol: RDY) crossed below their 200 day moving average of $14.14, changing hands as low as $13.42 per share. Dr. Reddy's Laboratories...
Nifty 50 top losers today, October 29: Dr. Reddy’s Laboratories, Coal India, Bharat Electronics, Eternal and more
Indian equity benchmarks ended higher on October 29, with the Nifty closing above the 26,000 mark. The Sensex gained 368.97...
Why Indian pharma giant Dr Reddy's is unfazed by Trump's tariff threats
Dr Reddy's CEO Erez Israeli says the pivot is already visible - India and Europe growth is now driven by innovation, consumer health and branded products, not just U.S. generics.
Dr Reddy's Laboratories Ltd (RDY) (Q2 FY26) Earnings Call Highlights: Navigating Growth Amidst ...
Dr Reddy's Laboratories Ltd (RDY) (Q2 FY26) Earnings Call Highlights: Navigating Growth Amidst Market Challenges
Half Year 2026 Dr Reddy's Laboratories Ltd Earnings Call Transcript
Half Year 2026 Dr Reddy's Laboratories Ltd Earnings Call Transcript
Nuvama positive on Dr. Reddy’s, highlights strong Q2 beat and focus on semaglutide approval
Nuvama Institutional Equities has maintained its buy rating on Dr. Reddy’s Laboratories with a target price of ₹1,475 per share...
Dr. Reddy's Laboratories Q2 Profit Rises
(RTTNews) - Dr. Reddy's Laboratories Ltd. (ROY) reported, under IFRS standards, that its second quarter profit attributable to equity holders of the parent company increased to INR 14.37 billion or IN...
Dr. Reddy's Laboratories Limited (RDY) Q2 2026 Earnings Call Transcript
Dr. Reddy’s Laboratories Q2 Results: Revenue rises 9.8% YoY to Rs 8,805 crore, net profit up 14%
Dr. Reddy’s Laboratories today announced its consolidated financial results for the quarter and half year ended September 30, 2025. The...
Top Q2 results today, October 24: Dr. Reddy’s Laboratories, Coforge, SBI Cards, ITC Hotels and more to announce earnings
Nearly two dozen companies are set to declare their financial results for the second quarter of FY2025-26 on Thursday, October...
Dr. Reddy’s Laboratories receives EIR from USFDA for Srikakulam facility
Dr. Reddy’s Laboratories has announced an important update regarding its formulations manufacturing facility, FTO 11, located in Srikakulam, Andhra Pradesh,...